Business Context and Reporting Period
This Form 6-K/A filing by GlaxoSmithKline plc covers the period ending February 2015. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMR) or connected persons, specifically regarding the GlaxoSmithKline Share Value Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed is the fair market value of American Depositary Shares (ADS) at $47.94 per ADS on February 18, 2015, used for tax withholding calculations.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a specific transaction where 790 ADSs were withheld to meet tax liabilities following the vesting of awards granted in 2012.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is strictly a regulatory disclosure of a share transaction involving Dr. M. Slaoui (Executive Director) and his connected person, Mrs. K. Slaoui, notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Investor Verification Checklist
- Verify the total number of ADSs held by Dr. M. Slaoui and Mrs. K. Slaoui post-transaction.
- Confirm the vesting schedule and terms of the 2012 Share Value Plan awards.
- Review the company's broader insider trading activity for the same period.